Clinical Pharmacology

Episodes 1-11 of 11

• • 

    

    Monica L. Baskin, PhD

    Peer

  • 

    

    Josep M. Llovet, MD, PhD

    Peer

  3

  

  RestartResume

  Advocating for Action in HCC: Delivering Impartial and Personalized Care

  RestartResume

  Advocating for Action in HCC: Delivering Impartial and Personalized Care

  1.00 credits

  Advocating for Action in HCC: Delivering Impartial and Personalized Care

  1.00 credits

• • 

    

    Jennifer W. Carlisle, MD

    Peer

  • 

    

    Suresh S. Ramalingam, MD

    Peer

  7

  

  RestartResume

  An Evolving Clinical Landscape in HER2+ and HER2-Mutant Metastatic NSCLC: Critical Updates for Your Practice

  RestartResume

  An Evolving Clinical Landscape in HER2+ and HER2-Mutant Metastatic NSCLC: Critical Updates for Your Practice

  0.50 credits

  An Evolving Clinical Landscape in HER2+ and HER2-Mutant Metastatic NSCLC: Cri...

  0.50 credits

• • 

    

    Yohann Loriot, MD, PhD

    Peer

  • 

    

    Robert J. Motzer, MD

    Peer

  9

  

  RestartResume

  Principles and Practice Strategies for Immunotherapy in Genitourinary Malignancies

  RestartResume

  Principles and Practice Strategies for Immunotherapy in Genitourinary Malignancies

  1.00 credits

  Principles and Practice Strategies for Immunotherapy in Genitourinary Maligna...

  1.00 credits

• • 

    

    Edward Chu, MD

    Peer

  • 

    

    Michael J. Overman, MD

    Peer

  7

  

  RestartResume

  Keeping Pace in GI Cancer: Advances in Immunotherapy in MSI-H/dMMR Metastatic Colorectal Cancer

  RestartResume

  Keeping Pace in GI Cancer: Advances in Immunotherapy in MSI-H/dMMR Metastatic Colorectal Cancer

  0.25 credits

  Keeping Pace in GI Cancer: Advances in Immunotherapy in MSI-H/dMMR Metastatic...

  0.25 credits

• • 

    

    Ajay K. Gopal, MD

    Peer

  0

  

  RestartResume

  Expert Answers to Common Questions for Advancing the Standard of Care for Relapsed/Refractory Follicular Lymphoma

  RestartResume

  Expert Answers to Common Questions for Advancing the Standard of Care for Relapsed/Refractory Follicular Lymphoma

  0.25 credits

  Expert Answers to Common Questions for Advancing the Standard of Care for Rel...

  0.25 credits

• • 

    

    Ruben A. Mesa, MD, FACP

    Peer

  5

  

  RestartResume

  Part 1: Improving Quality of Care and Shared Decision-Making in Myelofibrosis

  RestartResume

  Part 1: Improving Quality of Care and Shared Decision-Making in Myelofibrosis

  0.50 credits

  Part 1: Improving Quality of Care and Shared Decision-Making in Myelofibrosis

  0.50 credits

• • 

    

    Ruben A. Mesa, MD, FACP

    Peer

  5

  

  RestartResume

  Part 2: Improving Quality of Care and Shared Decision-Making in Myelofibrosis

  RestartResume

  Part 2: Improving Quality of Care and Shared Decision-Making in Myelofibrosis

  0.50 credits

  Part 2: Improving Quality of Care and Shared Decision-Making in Myelofibrosis

  0.50 credits

• • 

    

    Karen Reckamp, MS, MD

    Peer

  • 

    

    Heather Wakelee, MD

    Peer

  6

  

  RestartResume

  Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era

  RestartResume

  Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era

  1.00 credits

  Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment...

  1.00 credits

• • 

    

    Karen Reckamp, MS, MD

    Peer

  • 

    

    Heather Wakelee, MD

    Peer

  7

  

  RestartResume

  Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era: A Video-based Patient Case Series

  RestartResume

  Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era: A Video-based Patient Case Series

  0.50 credits

  Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment...

  0.50 credits

• • 

    

    John J. Russell, MD

    Peer

  • 

    

    Meredith Wadman, BM, BCh, M.S.

    Peer

  6

  

  RestartResume

  The Vaccine Race: Science, Politics, & the Human Costs of Defeating Disease

  RestartResume

  The Vaccine Race: Science, Politics, & the Human Costs of Defeating Disease

  The Vaccine Race: Science, Politics, & the Human Costs of Defeating Disease
• 5

  

  RestartResume

  Long-Term Aspirin Use Associated with Decreased Cancer Risk

  RestartResume

  Long-Term Aspirin Use Associated with Decreased Cancer Risk

  Long-Term Aspirin Use Associated with Decreased Cancer Risk